Status:
WITHDRAWN
Patient-derived-organoid (PDO) Guided Versus Conventional Therapy for Advanced Inoperable Abdominal Tumors
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Organoids
Eligibility:
All Genders
18-100 years
Phase:
PHASE2
Brief Summary
Recent studies that ex vivo drug responses on PDO models across different solid tumours can predict treatment responses to chemotherapeutic agents. In patients with metastatic or inoperable solid abdo...
Detailed Description
Precision oncology aims to improve the clinical outcomes of patients by offering personalized treatment through identifying druggable genomic aberrations within their tumours. However, current challen...
Eligibility Criteria
Inclusion
- patients should be older than 18 years, able to provide written consents to trial participation, with Eastern cooperative oncology group performance status of 0 or 1, With measurable disease in accordance with response evaluation criteria in solid tumours (RECIST) version 11. \[ 10 \] With a neutrophil count, hemoglobin \> 9g/dl, serum creatinine \<1.5 x upper limit of normal, serum bilirubin \< 1.5 x normal, and aspartate and alanine aminotransferases (\<3 x ULN or \<5x in those with liver metastasis) Ejection Fraction \>50% of normal. The disease is accessible for a biopsy (radiologic or endoscopic) or resection of a metastatic site.
Exclusion
- unable to give consent, could not obtain a biopsy
Key Trial Info
Start Date :
July 4 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 3 2025
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05378048
Start Date
July 4 2022
End Date
July 3 2025
Last Update
March 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of surgery , Prince of Wales Hospital
Hong Kong, N.T., Hong Kong